NDAORAL-21TABLET
Approved
Oct 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MODICON 21 (ethinyl estradiol; norethindrone) by Johnson & Johnson. Approved for pregnancy. First approved in 1974.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODICON 21 is an oral contraceptive combining ethinyl estradiol (estrogen) and norethindrone (progestin) in a 21-day tablet formulation. It prevents pregnancy through hormonal suppression of ovulation and alteration of cervical mucus. This is a foundational combination oral contraceptive that has been a standard-of-care option for decades.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential contraction of brand team resources and shift toward generic/lifecycle management strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
MODICON 21 offers limited career growth due to its LOE-approaching status and minimal linked job openings (0 identified). Roles on this product focus on defensive brand protection, compliance, and supply-chain optimization rather than innovation or expansion.
Brand Manager (Legacy/Lifecycle Management)
Worked on MODICON 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.